Infectious Disease Clinical Trial
Official title:
Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series
This is the first Case Studies article highlight factors determine the effectiveness of Convalescent Plasma Therapy (CPT) in Indonesia, accompanied by supporting data and images before and after the patients received the therapy. This Case Studies gives a huge contribution as CPT still on going as multicentre study and apply massively as emergency approved treatment in Indonesia.
Eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320. This study has three goals included to detect the improvement of patient clinical and laboratory conditions, safety of CPT, and conversion from positive to negative results after CPT administration. Convalescent plasma applied within two weeks (13 days) from onset of illness and within a week (6.5 days) from the first day of hospital admission for all patients. Improvements in clinical symptoms, laboratory parameters, thorax photo, negative conversion of PCR, and decreased oxygen supplementation occurred within a week after CPT. Patients with two doses of CP tended to have faster recovery than those with one dose of CP. No severe adverse effects were observed in any patient. This is the first case series in Indonesia showing CPT is safe and well tolerated, and early CPT before the patient is intubated could potentially prevent disease progression, increase the recovery rate, and shorten the inpatient days. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05568953 -
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
|
Phase 2 | |
| Completed |
NCT04568889 -
Minnesota COVID-19 Testing Project
|
N/A | |
| Completed |
NCT06063330 -
Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
|
Phase 1 | |
| Completed |
NCT01198925 -
Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion
|
Phase 4 | |
| Completed |
NCT05063812 -
Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
|
||
| Recruiting |
NCT06004739 -
Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection
|
N/A | |
| Not yet recruiting |
NCT03636711 -
Antibiotic Stewardship in Infectious Disease Departement
|
||
| Completed |
NCT03457688 -
Effect of Prebiotic Fructans to Reduce Number of Febrile Infections in Children
|
N/A | |
| Completed |
NCT03241355 -
Prebiotic Fructans on the Incidence of Acute Infectious Diseases in Children
|
N/A | |
| Terminated |
NCT05420077 -
Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273
|
Phase 1 | |
| Completed |
NCT04084106 -
Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota
|
Phase 4 | |
| Recruiting |
NCT05013944 -
AnovaOS Network Powered Patient Registry
|
||
| Completed |
NCT03893279 -
Perception of Smell and Taste During Antibiotic Treatment
|
||
| Active, not recruiting |
NCT05619770 -
Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects
|
Phase 1 | |
| Completed |
NCT01772901 -
Brief Influenza Vaccine Education to Pregnant Women
|
N/A | |
| Completed |
NCT05413772 -
Temocillin in ESBL-Enterobacteriaceae Infections
|
||
| Recruiting |
NCT04319328 -
Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
|
||
| Completed |
NCT04613271 -
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
|
Phase 3 | |
| Completed |
NCT03239665 -
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
|
N/A | |
| Completed |
NCT03224026 -
Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without Source
|